Newer therapies are needed for the treatment of status epilepticus (SE) refractory to benzodiazepines. Enhanced glutamatergic neurotransmission leads to SE, and AMPA receptors are modified during SE. Reducing glutamate release during SE is a potential approach to terminate SE. The neuropeptide somatostatin (SST) is proposed to diminish presynaptic glutamate release by activating SST type-2 receptors (SST2R). SST exerts an anticonvulsant action in some experimental models of seizures. Here, we investigated the mechanism of action of SST on excitatory synaptic transmission at the Schaffer collateral-CA1 synapses and the ability of SST to treat SE in rats using patch-clamp electrophysiology and video-EEG monitoring of seizures. SST reduced action potential-dependent EPSCs (sEPSCs) at Schaffer collateral-CA1 synapses at concentrations up to 1 μM; higher concentrations had no effect or increased the sEPSC frequency. SST also prevented paired-pulse facilitation of evoked EPSCs and did not alter action-potential-independent miniature EPSCs (mEPSCs). The effect of SST on EPSCs was inhibited by the SST2R antagonist cyanamid-154806 and was mimicked by the SST2R agonists, octreotide and lanreotide. Both SST and octreotide reduced the firing rate of CA1 pyramidal neurons. Intraventricular administration of SST, within a range of doses, either prevented or attenuated pilocarpine-induced SE or delayed the median time to the first grade 5 seizure by 11 min. Similarly, octreotide or lanreotide prevented or attenuated SE in more than 65% of animals. Compared to the pilocarpine model, octreotide was highly potent in preventing or attenuating continuous hippocampal stimulation-induced SE in all animals within 60 min of SE onset. Our results demonstrate that SST, through the activation of SST2Rs, diminishes presynaptic glutamate release and attenuates SE.
Introduction
Novel therapies are needed for the treatment of status epilepticus (SE), which is currently treated with benzodiazepines, barbiturates, and anesthetics such as propofol and midazolam, all of which enhance GABAergic inhibition (Meierkord et al., 2010) . However, GABAergic inhibition is compromised during SE (Goodkin et al., 2005 (Goodkin et al., , 2008 Kapur and Macdonald, 1997; Naylor et al., 2005) , and pharmacoresistance to benzodiazepines develops (Meierkord et al., 2010; Neligan and Shorvon, 2010; Treiman et al., 1998 ). An alternate approach to treat SE is to reduce excitatory neurotransmission. The activation of muscarinic receptors increases glutamate release from presynaptic terminals of hippocampal principal neurons (Kozhemyakin et al., 2010; Olivos and Artalejo, 2008; Sun and Kapur, 2012) and can cause SE in humans and experimental animals (McDonough and Shih, 1997; Okumura et al., 1996; Turski et al., 1989) . Furthermore, AMPA receptors (AMPARs) expressed on CA1 pyramidal neurons of the hippocampus are modified during SE (Rajasekaran et al., 2012) . The blockade of AMPARs can terminate benzodiazepine-refractory SE (Fritsch et al., 2010; Rajasekaran et al., 2012) , suggesting that inhibiting postsynaptic excitatory receptors can terminate SE. A similar approach to reduce the strength of glutamatergic transmission during SE is to reduce the release of neurotransmitter.
Somatostatin (SST) is proposed to reduce glutamatergic neurotransmission (Boehm and Betz, 1997). However, studies on SST and glutamatergic neurotransmission were performed on cultured hippocampal neurons at autaptic synapses (Boehm and Betz, 1997), which do not occur in intact hippocampal preparations. Furthermore, it is difficult to clearly differentiate between pre-and post-synaptic effects in autaptic preparations. The actions of SST are mediated by SST receptor (SSTR) subtypes 1-5, which are widely distributed throughout the brain (Hoyer et al., 1995; Schulz et al., 2000) . Immunocytochemical studies demonstrate that SST2R is located on the soma, dendrites, and axons of hippocampal neurons, suggesting that SST2R may mediate both the presynaptic and postsynaptic effects of SST (Dournaud et al., 
